Consensus Blueprint Medicines Corporation

Equities

BPMC

US09627Y1091

Market Closed - Nasdaq 04:00:00 2024-05-17 pm EDT 5-day change 1st Jan Change
105 USD -1.58% Intraday chart for Blueprint Medicines Corporation -1.63% +13.79%

Evolution of the average Target Price on Blueprint Medicines Corporation

Price target over the last 5 years

History of analyst recommendation changes

8bd17ad9cd76e33c6b.EczB4diIQicmPkTyjEMjzdVszk46QLLigIDEisaA_co.Q67xi4nMcmVSBwGH0ykOn5Qkog1UFuWayrmL8I3uvv5iuPCjrLgPXRddBQ~d19bef9483d4f8157f67e265068c3600
Stephens Starts Blueprint Medicines With Overweight Rating, $140 Price Target MT
Blueprint Medicines Insider Sold Shares Worth $1,050,000, According to a Recent SEC Filing MT
Goldman Sachs Adjusts Price Target on Blueprint Medicines to $168 From $121, Maintains Buy Rating MT
Leerink Upgrades Blueprint Medicines to Market Perform, Price Target at $97 MT
Wedbush Raises Blueprint Medicines' Price Target to $120 From $110 After Stronger-Than-Expected Q1 Results, Keeps Outperform Rating MT
Wedbush Adjusts Blueprint Medicines' PT to $110 From $97, Keeps Outperform Rating MT
Barclays Increases Price Target on Blueprint Medicines to $70 From $58, Maintains Equalweight Rating MT
Oppenheimer Raises Blueprint Medicines Price Target to $90 From $85, Maintains Outperform Rating MT
Stifel Adjusts Blueprint Medicines' Price Target to $97 From $95, Keeps Buy Rating MT
Wedbush Lowers Blueprint Medicines' PT to $97 From $100 After Discussion of Strategic Priorities for 2024, Pipeline Update; Keeps Outperform Rating MT
Raymond James Adjusts Blueprint Medicines' Price Target to $100 From $85, Keeps Strong Buy Rating MT
Wells Fargo Raises Blueprint Medicines Price Target to $115 From $86, Maintains Overweight Rating MT
Wedbush Raises Blueprint Medicines Price Target to $100 From $80, Maintains Outperform Rating MT
North American Morning Briefing : Rate Decisions, -2- DJ
Morgan Stanley Adjusts Price Target on Blueprint Medicines to $63 From $59, Maintains Equalweight Rating MT
Barclays Raises Price Target on Blueprint Medicines to $58 From $46, Maintains Equalweight Rating MT
Needham Raises Blueprint Medicines Price Target to $74 From $66, Maintains Buy Rating MT
Oppenheimer Upgrades Blueprint Medicines to Outperform From Perform, $85 Price Target MT
Wedbush Raises Blueprint Medicines' Price Target to $80 From $75 After Higher-Than-Expected Q3 Financial Results, Keeps Outperform Rating MT
Needham Adjusts Price Target on Blueprint Medicines to $66 From $65, Maintains Buy Rating MT
Goldman Sachs Adjusts Price Target on Blueprint Medicines to $83 From $93, Maintains Buy Rating MT
Morgan Stanley Adjusts Price Target on Blueprint Medicines to $59 From $55, Maintains Equal-Weight Rating MT
Wells Fargo Upgrades Blueprint Medicines to Overweight From Equalweight, Adjusts Price Target to $82 From $55 MT
Wells Fargo Raises Price Target on Blueprint Medicines to $55 From $48, Maintains Equal-Weight Rating MT
SVB Securities Downgrades Blueprint Medicines to Underperform From Market Perform, Cuts Price Target to $43 From $48 MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
105 USD
Average target price
119.4 USD
Spread / Average Target
+13.77%
High Price Target
168 USD
Spread / Highest target
+60.06%
Low Price Target
75 USD
Spread / Lowest Target
-28.54%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Blueprint Medicines Corporation

Stephens Inc.
Goldman Sachs
Leerink Partners
Wedbush
Barclays
Oppenheimer
Stifel Nicolaus
Raymond James
Wells Fargo Securities
Needham & Co.
Morgan Stanley
SVB Securities LLC
Guggenheim
HC Wainwright
Berenberg Bank
Jefferies & Co.
Citigroup
Piper Sandler
Baird
SVB Leerink
Credit Suisse
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
  1. Stock Market
  2. Equities
  3. BPMC Stock
  4. Consensus Blueprint Medicines Corporation
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW